Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre

Arjona-Sánchez, Á; Muñoz-Casares, F. C; Rufián-Peña, S; Díaz-Nieto, R; Casado-Adam, Á; Rubio-Pérez, M. J; Ortega-Salas, R.
Clin. transl. oncol. (Print) ; 13(4): 261-267, abr. 2011. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-124433

Documentos relacionados

  1. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei.
  2. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
  3. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
  4. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
  5. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score.
  6. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
  7. Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.
  8. A Proposal for Modification of the PSOGI Classification According to the Ki-67 Proliferation Index in Pseudomyxoma Peritonei.
  9. Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study.
  10. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).